Rod Wong – Empty Rooms: Innovation in Biotech at RTW (Capital Allocators, EP. 310)

Episode Summary

Executive Summary: Rod Wong, founder of RTW Investments, explains how biotech investing has evolved from stock picking into full-lifecycle company building, driven by cheaper genomic information, new drug modalities, and RTW’s growing capabilities across public, private, and transactional investing. He argues the sector’s innovation boom will outweigh pricing pressure, but success requires disciplined probability assessment, structured team processes, and careful risk management in a highly binary industry.

Main Topics: Rod Wong’s path into medicine and biotech investing (Priority: 4/5): Wong traces his interest in science to his parents, then describes how economics opened a parallel path that led him from pre-med ambitions into biotech research and investing. Why biotech remains an attractive but difficult asset class (Priority: 5/5): He makes the case that biotech is in a major innovation boom, with cheaper information and new modalities expanding the number of addressable therapies, even as the industry experiences deep bear-market volatility. RTW’s evolution from stock picker to full-lifecycle investor (Priority: 5/5): RTW has expanded beyond public equities into private company creation, crossover investing, royalties, licensing, and operational support, enabling it to participate across a drug’s entire development path. Building a scalable organization around science and process (Priority: 5/5): Wong details the challenge of turning a small, talented investing team into a coordinated institution with specialists, managers, consultants, training, and process tools like slide decks and Gantt charts. Probability, portfolio construction, and risk control in binary assets (Priority: 5/5): He explains RTW’s re-underwriting framework, concentration limits, and asymmetric bet sizing, including how they manage downside in a business where outcomes are often binary and highly volatile. Competition, market structure, and industry headwinds (Priority: 4/5): Wong describes a relatively small healthcare-dedicated investing ecosystem and highlights structural pressures from pharma patent cliffs, biotech financing challenges, payer pressure, and a more conservative FDA.

Key Arguments: Biotech is compelling now because the sector is in a multi-decade innovation cycle driven by cheap genomic information and a much broader toolkit of drug modalities. Even with pricing pressure, more approved drugs and more effective therapies should create substantial value because drug development still captures meaningful value through pricing. Great biotech investing requires finding underappreciated assets early, then supporting them across multiple stages so winners can compound over years. The best investment process in this space combines scientific expertise, statistical rigor, commercial diligence, and deep assessment of management quality. As RTW grew, it had to solve the harder problem of scaling culture and structure, not just analyze science better; process and management quality became critical. A smaller, concentrated portfolio is rational because high-probability asymmetric opportunities are scarce, and the asset class is inherently binary and volatile. Private investments now function as a farm team that feeds the public portfolio and gives RTW more time to diligence assets and teams. The biggest long-term risk to the industry is payer pressure on drug prices; a near-term issue is a more conservative FDA after COVID-related burnout and turnover.

Data Points: RTW assets under management: $6 billion - Rod Wong describes the firm as a life sciences-focused investment and innovation firm. RTW headcount: 80 professionals - Size of the organization during the interview. Biotech bear market duration: 18 months - Wong characterizes the environment as a prolonged correction. Magnitude of bear market: Second worst correction in industry history - He compares it to the genomics bubble burst from 2000-2003. Genome sequencing cost (first draft): $300 million - Wong uses this to show how information has become dramatically cheaper. Genome sequencing cost today: A few hundred dollars - He cites this as a core driver of biotech innovation. Approved drugs per year: About 40 historically - He uses this to frame expected increases in innovation output. Potential future approved drugs per year: About 80 - Illustrative doubling used to show value creation despite pricing pressure. Private investment volume: 10 to 20 investments per year - RTW’s crossover and company-creation activity. Public/private mix: About 80% public / 20% private - Current portfolio composition. Net long exposure: About 70% net long - RTW flagship fund positioning at the time of the interview. Long exposure: About 90%+ invested long - Gross long side of the portfolio. Gross exposure: About 90 by 20 - Wong describes it as roughly 90% long and 20% short. Outer bounds of net exposure: 30% to 90% net long - He describes typical portfolio range. High-end gross exposure: About 150% - Upper range of gross positioning. Allowed loss on best ideas: Up to 5% - RTW’s guidepost for sizing highest-conviction positions. Prediction hit rate: High 60s to 70% - Wong references their ability to predict drug success. Typical annual charity of portfolio events: Not specified - No exact number given; RTW re-underwrites continuously around upcoming events. Loser rate: High 30s to 40% - Wong says the firm is wrong this often in a binary space. Large position size: 5% to 10%+ - Used for companies with base business value and additional upside. Small position size: Less than 5% - Used for single-product development-stage companies with near-total downside risk. RTW Office crisis year: 2011 - He recalls losing the firm’s biggest client and shrinking assets sharply. Largest client loss: Assets went from small to two-thirds smaller - Describes the severity of the 2011 setback. Top 10 winners and losers: Over 10 approved drugs among winners - He points to this slide as the best window into RTW’s process. Second largest loser example: Map Pharma short - A short position that lost because the company was sold before regulatory failure.

Pivotal Quotes: "We are in the mid to early innings of what I would call the biggest innovation boom our sector industry has ever seen." — Rod Wong: On the outlook for biotech innovation and why he remains constructive despite the bear market. "Now we’re very much not just stock pickers... we’re what we call full lifecycle investors." — Rod Wong: Explaining RTW’s transformation from public-market investing into company building and multi-stage capital support. "If you’re going to make a decision based on planning, plan for a not straight line and don’t make it a two-year plan, make it a five or a 10-year plan." — Rod Wong: Advice about entrepreneurship, endurance, and surviving difficult periods like RTW’s 2011 setback.

Implications: Biotech investing is becoming more complex but also more opportunity-rich. Firms that combine scientific depth, operational capability, and disciplined risk management should gain an edge as innovation broadens and capital becomes more selective.